Cogentix Medical, Inc. (NASDAQ:CGNT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “

Cogentix Medical (CGNT) traded up 2.022% during midday trading on Tuesday, hitting $2.775. The company’s stock had a trading volume of 18,440 shares. Cogentix Medical has a 12 month low of $1.37 and a 12 month high of $3.26. The company’s 50 day moving average price is $2.46 and its 200 day moving average price is $1.96. The firm’s market cap is $169.04 million.

Cogentix Medical (NASDAQ:CGNT) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The firm had revenue of $14.06 million during the quarter, compared to the consensus estimate of $13.90 million. Cogentix Medical had a negative net margin of 35.88% and a negative return on equity of 13.83%. Analysts expect that Cogentix Medical will post ($0.03) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/cogentix-medical-inc-cgnt-rating-lowered-to-hold-at-zacks-investment-research.html.

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its holdings in Cogentix Medical by 2.3% in the 1st quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock worth $1,013,000 after buying an additional 12,459 shares during the period. Broadfin Capital LLC boosted its holdings in Cogentix Medical by 45.2% in the 2nd quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock worth $1,905,000 after buying an additional 340,771 shares during the period. Finally, Northern Trust Corp boosted its holdings in Cogentix Medical by 0.4% in the 2nd quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock worth $129,000 after buying an additional 326 shares during the period. 12.67% of the stock is owned by institutional investors.

About Cogentix Medical

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Receive News & Stock Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related stocks with our FREE daily email newsletter.